Patient characteristics and HbA1c ranges
| Patient characteristics | Variable | N (% of patients within characteristic group) | Tight control: HbA1c<7%, N (% of patients within HbA1c control range) | Moderate control: HbA1c 7%–8.5%, N (% of patients within HbA1c control range) | Not controlled: HbA1c >8.5%, N (% of patients within HbA1c control range) |
| All patients in sample | 30 416 | 16 705 (54.92) | 9298 (30.57) | 4413 (14.51) | |
| Age range in years | 40–49 | 2506 (8.24) | 1162 (46.37) | 687 (27.41) | 657 (26.22) |
| 50–59 | 6253 (20.56) | 3123 (49.94) | 1833 (29.31) | 1297 (20.74) | |
| 60–69 | 9041 (29.72) | 4902 (54.22) | 2816 (31.15) | 1323 (14.63) | |
| 70–79 | 7545 (24.80) | 4414 (58.53) | 2420 (32.07) | 709 (9.04) | |
| 80+ | 5073 (16.68) | 3104 (61.19) | 1542 (30.40) | 427 (8.42) | |
| Number of comorbidities* | 0–1 | 6783 (22.30) | 3398 (50.10) | 2197 (32.39) | 1188 (17.51) |
| 2–3 | 20 578 (67.6) | 11 430 (55.55) | 6268 (30.46) | 2880 (13.99) | |
| 4 or more | 3055 (10.04) | 1877 (61.44) | 833 (27.27) | 345 (11.29) | |
| Gender | Male | 15 942 (52.41) | 8532 (53.53) | 4945 (31.02) | 2463 (15.45) |
| Female | 14 475 (47.59) | 8172 (56.46) | 4353 (30.07) | 1950 (13.47) | |
| Missing | 1 (0) | - | - | - | |
| sBP >130 mm Hg | No | 15 821 (52.02) | 8985 (56.79) | 4662 (29.47) | 2174 (13.74) |
| Yes | 12 338 (40.56) | 6601 (53.51) | 3870 (31.36) | 1867 (15.13) | |
| Missing | 2257 (7.42) | 1119 (49.58) | 766 (33.94) | 372 (16.48) | |
| LDL in mmol/L | <2 | 14 018 (46.09) | 7451 (56.15) | 4738 (33.80) | 1829 (13.05) |
| >2 | 14 190 (46.65) | 8194 (57.75) | 3877 (27.32) | 2119 (14.93) | |
| Missing | 2208 (7.26) | 1060 (48.01) | 683 (30.93) | 465 (21.06) | |
| Urine albumin to creatinine ratio | <2 | 8328 (27.38) | 4452 (53.46) | 2725 (32.72) | 1151 (13.82) |
| >2 | 6570 (21.60) | 2944 (44.81) | 2273 (34.60) | 1353 (20.59) | |
| Missing | 15 518 (51.02) | 9309 (59.99) | 4300 (27.71) | 1909 (12.30) | |
| BMI | <25 | 3320 (10.92) | 2039 (61.42) | 890 (26.81) | 391 (11.78) |
| 25–29.9 | 7564 (24.87) | 4426 (58.52) | 2270 (30.01) | 868 (11.47) | |
| >30 | 12 632 (41.53) | 6699 (53.04) | 3924 (31.06) | 2009 (15.90) | |
| Missing | 6900 (22.69) | 3541 (51.32) | 2214 (32.09) | 1145 (16.59) | |
| Number of encounters in the past 2 years | 1–5 | 4012 (13.19) | 2243 (55.91) | 1144 (28.51) | 625 (15.58) |
| 6–16 | 15 199 (49.97) | 8603 (56.61) | 4577 (30.11) | 2019 (13.28) | |
| 17 or more | 11 205 (36.84) | 5859 (52.29) | 3577 (31.92) | 1769 (15.79) | |
| Number of classes of medication prescribed | 0 (no diabetic medications) | 19 353 (63.62) | 11 990 (61.95) | 5004 (25.86) | 2359 (12.19) |
| 1 (1 class of medications) | 5991 (19.70) | 3295 (55.00) | 2070 (34.55) | 626 (10.45) | |
| 2 (2 classes of medications) | 2086 (6.86) | 780 (37.39) | 912 (43.72) | 394 (18.89) | |
| 3 (3 classes of medications or insulin) | 2986 (9.82) | 640 (21.43) | 1312 (43.94) | 1034 (34.63) |
*Includes the CPCSSN validated comorbidities only (hypertension, chronic obstructive pulmonary disease, depression, osteoarthritis, dementia, epilepsy, Parkinson's disease).
BMI, body mass index; HbA1c, hemoglobin A1c; LDL, low density lipoprotein; sBP, systolic blood pressure.